ONS Putting Evidence Into Practice (PEP) resources are designed to provide evidence-based interventions for patient care and teaching. PEP topic teams of nurse scientists, advanced practice nurses, and staff nurses summarize and synthesize the available evidence in PEP topic areas. These resources can be used to plan individual patient care, patient education, nursing education, quality improvement, and research.
If you have a question about how to apply these PEP topics to your practice, ask a nurse on ONS staff.
Before you get started, here's a brief overview of PEP terminology.
Users of the PEP information should be aware that the evidence provided here is mostly limited to management of symptoms associated with chemotherapy and radiation therapy. The interventions as categorized here may not be applicable to the same symptoms caused by immunotherapies. The mechanisms of symptom development secondary to immunotherapies, immune-related adverse events (irAEs), are different from those of more traditional treatments, so the interventions identified currently in the PEP evidence may not be applicable and consequences of those symptoms can be much more extreme. Evidence regarding interventions for symptoms associated with immunotherapy is currently limited; however, the critical aspect for management is the immediate identification of the symptom and early intervention (Davies, 2014).
Clinicians should review drug specific information about assessment for and management of irAEs. The need to report all symptoms promptly must be specifically emphasized in patient teaching. Some adverse events can occur months after the end of treatment. Patients must be aware of the need to report late symptoms and continue follow-up throughout and after treatment (Ledezma & Heng, 2014).
Further information about immunotherapy treatment and observed irAEs can be obtained through ONS courses.
Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., ... Hallmeyer, S. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36, 1714–1768. https://doi.org/10.1200/JCO.2017.77.6385
Davies, M. (2014). New modalities of cancer treatment for NSCLC: Focus on immunotherapy. Cancer Management and Research, 4, 63–75. doi:10.2147/CMAR.S57550
Ledezma, B., & Heng, A. (2014). Real-world impact of education: Treating patients with ipilimumab in community practice setting. Cancer Management and Research, 4(6), 5–14. doi:10.2147/CMAR.S5254
Interventions for which effectiveness has been demonstrated by strong evidence from rigorously designed studies, meta-analysis, or systematic reviews and for which expectation of harm is small compared to the benefits
Interventions for which effectiveness has been demonstrated from a single rigorously conducted controlled trial, consistent supportive evidence from well-designed controlled trials using small samples, or guidelines developed from evidence and supported by expert opinion
Interventions for which clinicians and patients should weigh the beneficial and harmful effects according to individual circumstances and priorities
Interventions for which insufficient or conflicting data or data of inadequate quality currently exist, with no clear indication of harm
Interventions for which lack of effectiveness has been demonstrated by negative evidence from a single rigorously conducted controlled trial, consistent negative evidence from well-designed controlled trials using small samples, or guidelines developed from evidence and supported by expert opinion
Interventions for which lack of effectiveness or harmfulness has been demonstrated by strong evidence from rigorously conducted studies, meta-analyses, or systematic reviews, or interventions where the costs, burden, or harm associated with the intervention exceed anticipated benefit
Low-risk interventions that are consistent with sound clinical practice, suggested by an expert in a peer reviewed publication, and for which limited evidence exists (An expert is an individual who has published peer reviewed material in the domain of interest.)
ONS welcomes the opportunity to license our intellectual property. Email email@example.com any questions you may have or to initiate a licensing partnership with ONS.